Cardiology
Latest news
974 articles · 20 / page
VO2T12.5% Emerges as a Key Physiological Marker for Cardiac Performance and Treatment Efficacy in Obstructive HCM
A substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel, clinically relevant CPET metric that correlates with cardiac hemodynamics, predicts heart failure outcomes, and improves significantly with aficamten treatment in patients
Beyond Traditional Risk Scores: How Preclinical Measures Refine Heart Failure Prediction in the ARIC Study
Recent findings from the ARIC study reveal that integrating cardiac biomarkers and echocardiography with the PREVENT-HF score significantly enhances the prediction of incident heart failure, identifying high-risk individuals who traditional
Beyond Insulin Resistance: Why Diabetes Status Dictates the Cardiovascular Risk of the Triglyceride-Glucose Index
A prospective ARIC cohort study reveals that diabetes fundamentally modifies the relationship between the triglyceride-glucose (TyG) index and subclinical myocardial injury, shifting the risk profile from an L-shaped to a J-shaped associati
Mavacamten Significantly Reduces Myocardial Stress and Injury in Nonobstructive HCM: Insights From the ODYSSEY-HCM Trial
While the ODYSSEY-HCM trial missed its primary functional endpoints, a new exploratory analysis reveals that mavacamten significantly reduces NT-proBNP and hs-cTnI levels in patients with nonobstructive hypertrophic cardiomyopathy, suggesti
High-Sensitivity Cardiac Troponin Risk Stratification Safely Accelerates ED Discharge and Improves 1-Year Outcomes
A secondary analysis of the HiSTORIC trial reveals that using high-sensitivity cardiac troponin for risk stratification significantly reduces ED length of stay and increases safe discharge rates for low- and intermediate-risk patients, with
Beyond Peak VO2: VO2T12.5% Emerges as a Cardiospecific Marker of Performance and Therapeutic Response in Obstructive HCM
This substudy of the SEQUOIA-HCM trial identifies VO2T12.5% as a novel exercise recovery metric. It uniquely reflects cardiac hemodynamics, predicts clinical outcomes, and demonstrates significant improvement with aficamten therapy, offerin
A Unified High-Sensitivity Cardiac Troponin I Threshold of 80 ng/L for Risk Stratification in Wild-Type Transthyretin Amyloid Cardiomyopathy
This multicenter study identifies high-sensitivity cardiac troponin I (hs-cTnI) as a potent, independent predictor of mortality in wild-type transthyretin amyloid cardiomyopathy. A universal threshold of 80 ng/L, integrated with natriuretic
Long-Term Silicon Exposure Fails to Predict Coronary Artery Disease Severity or Systemic Inflammation
A pilot study evaluating hair silicon as a long-term mineral marker found no significant association between silicon concentrations and coronary artery disease (CAD) severity or inflammatory markers, suggesting silicon may be metabolically
Calprotectin: A Mechanistically Informed Biomarker for Predicting Atherosclerotic Cardiovascular Disease
A longitudinal study from the Dallas Heart Study identifies calprotectin as a significant, independent predictor of ASCVD events, linking neutrophil activation to endothelial dysfunction and increased cardiovascular risk across diverse popu
Beyond Troponin: Cardiac Myosin-Binding Protein C Accelerates NSTEMI Diagnosis and Emergency Department Triage
A secondary analysis of the APACE study demonstrates that Cardiac Myosin-Binding Protein C (cMyC) significantly improves NSTEMI diagnosis, particularly in early presenters. Integrating cMyC with high-sensitivity troponin into a dual-biomark
Sacubitril-Valsartan Prevents Anthracycline-Induced Myocardial Dysfunction: Results from the SARAH Trial
The SARAH trial demonstrates that sacubitril-valsartan significantly reduces subclinical left ventricular dysfunction in patients with elevated troponin during anthracycline chemotherapy, potentially offering a new cardioprotective strategy
Troponin Assay Transitions: Increased Clinical Burden Without Improved Cardiovascular Outcomes
Switching from high-sensitivity troponin I to T significantly increases diagnoses of myocardial injury and hospital admissions without improving long-term cardiovascular outcomes, while low-threshold troponin I remains a safe tool for rapid
Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial
This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of
Beyond MACE: Semaglutide Significantly Reduces Hospitalization Burden in Patients with Obesity and Cardiovascular Disease
This exploratory analysis of the SELECT trial demonstrates that semaglutide 2.4 mg reduces total hospital admissions and total days spent in the hospital by approximately 10-11% in patients with established cardiovascular disease and obesit
Genetic Tug-of-War: How Polygenic Background Dictates the Penetrance and Phenotype of Monogenic Cardiomyopathies
A large-scale study from the Penn Medicine BioBank demonstrates that polygenic risk scores for hypertrophic and dilated cardiomyopathies act as bidirectional modifiers, influencing the clinical expression of rare pathogenic variants and off
Preoperative Cardiovascular Risk Does Not Dictate RAS Inhibitor Management: Insights from the STOP-or-NOT Trial
A post hoc analysis of the STOP-or-NOT trial demonstrates that preoperative cardiovascular risk stratification does not influence the outcomes of continuing versus discontinuing renin-angiotensin system inhibitors before major noncardiac su
Diabetes, Obesity, and Early Rhythm Control in Atrial Fibrillation: Insights from the EAST-AFNET 4 Trial
This analysis of the EAST-AFNET 4 trial highlights that early rhythm control therapy’s cardiovascular benefits and safety are consistent regardless of diabetes or obesity status in atrial fibrillation patients.
Obstructive Coronary Artery Disease Does Not Diminish Long-Term Health Status or Clinical Efficacy After TAVR: 3-Year Insights from SCOPE I
A post hoc analysis of the SCOPE I trial reveals that obstructive coronary artery disease (CAD) does not significantly impact 3-year survival or patient-reported health status following TAVR, questioning the routine necessity of periprocedu
Heart Failure Mortality: The Resilient Challenge in an Era of Declining Cardiovascular Deaths
This multi-national analysis of 2.92 million deaths highlights a concerning trend: while coronary and stroke mortality have plummeted, heart failure mortality remains stagnant or rising, with people with diabetes bearing a disproportionate
Ticagrelor Plus Aspirin Versus Aspirin Alone After Coronary Artery Bypass Grafting in Acute Coronary Syndrome: A Contemporary Evidence Synthesis
This review synthesizes current evidence on the efficacy and safety of ticagrelor combined with aspirin compared to aspirin alone following CABG for acute coronary syndrome, highlighting the 2025 TACSI trial and its implications for clinica
Browse by specialty
Open language-specific specialty feeds and department pages.